Dr. Reddy's Laboratories SA, Switzerland, a subsidiary of Dr. Reddy's, has entered into a definitive agreement with Haleon plc to acquire Nicotinell and related brands in the nicotine replacement therapy (NRT) category. The acquisition, which involves an upfront cash consideration of GBP 458 million, is valued at approximately 500 million pounds ($632.55 million). This move signifies a significant step for Dr. Reddy's in building its global consumer healthcare business. Haleon will sell its nicotine replacement therapy business outside the U.S. as part of this deal. Additionally, Dr. Reddy's will acquire NorthStar Switzerland and its related portfolio from Haleon.
Haleon to sell nicotine replacement therapy business outside US for $633 mln https://t.co/xondzFoDqx https://t.co/5eDWuiwEE8
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business $RDY https://t.co/J8FCUts6Qz
Dr Reddy's to acquire Haleon's nicotine replacement therapy portfolio for 500 million pounds @jpullokaran https://t.co/muB6guTf4S
Dr Reddy's Concall | Enters into a definitive agreement with Haleon plc to acquire consumer healthcare brands in Nicotine Replacement Therapy (“NRT”) category, outside the US Here are the details of the deal, OTC biz, pipeline and more👇 @drreddys @haleon_health #StockMarket https://t.co/2R0X0t8KwX
Haleon will sell its nicotine replacement therapy business outside the U.S. to a unit of India's Dr. Reddy's for 500 million pounds ($632.55 million), the British consumer healthcare company said on Wednesday. https://t.co/vDofMlSD3M https://t.co/vDofMlSD3M
#DrReddys' #Switzerland subsidiary to acquire #NorthStar Switzerland and related portfolio from #Haleon.
Stocks In News | Dr Reddy's: Unit entered into a definitive agreement with Haleon PLC and its associate cos @drreddys #StockMarket https://t.co/uyCozzm2bP
#DrReddy’s | Arm Reddy’s Laboratories SA, Switzerland enters into a definitive agreement with Haleon plc and its associate companies (“Haleon Group”) to acquire Nicotinell & related brands. For this acquisition, the arm will pay an upfront cash consideration of GBP 458 million… https://t.co/Xqil7DNzJT
Skyhawk Therapeutics announces expansion into new labs in Basel, Switzerland at SuperLab Suisse, enhancing research and development capabilities. #SkyhawkTherapeutics #BaselExpansion #R&D.
#JustIn | #RemediumLifecare bags multi-yr supply contract worth ₹175 cr from UK-based Aster Biotech https://t.co/9AqhjLSrAB